Core Insights - Nutriband Inc. has made significant progress in the commercialization of its AVERSA technology, aimed at improving the safety of transdermal drugs prone to abuse, particularly pain medications [4][6][10] Company Achievements - The company has established a partnership with Kindeva Drug Delivery to develop AVERSA Fentanyl, which is expected to be the first opioid pain patch with abuse deterrent properties [5][8] - Nutriband has expanded its intellectual property portfolio, securing patents in 46 countries, including recent approvals in China, Hong Kong, and the United States [9][15] - The company raised $8.4 million in April 2024 through a non-brokered private placement, primarily from existing shareholders, to support its development efforts [8] Financial Outlook - AVERSA Fentanyl is projected to achieve peak annual sales between $80 million and $200 million, while AVERSA Buprenorphine is estimated to reach peak sales of $70 million to $130 million [6] - The Pocono Pharma subsidiary is expected to have a strong revenue year in 2025 due to expanding collaborations in contract manufacturing services [11] Future Goals - Nutriband aims to initiate a pivotal Human Abuse Liability clinical trial for AVERSA Fentanyl in 2025, supporting an NDA filing with the FDA [10] - The company plans to explore international partnerships for its AVERSA intellectual property as it approaches the NDA filing [10]

Financial Performance - For the year ending January 31, 2025, the company generated revenue of $2,139,537, a 2.6% increase from $2,085,314 in the previous year[165]. - The company's gross margin for the year ending January 31, 2025, was $743,317, down from $862,105 in the prior year, primarily due to lower margins on tape sales[165]. - The company incurred a net loss of $10,482,617, or $(0.99) per share, for the year ended January 31, 2025, compared to a loss of $5,485,314, or $(0.69) per share, for the previous year[171]. - Selling, general and administrative expenses increased to $4,313,810 for the year ending January 31, 2025, from $3,773,606 in the previous year, primarily due to higher non-cash compensation and public relations costs[166]. - The company has not generated any revenue from its 4P Therapeutics segment for the year ending January 31, 2025, due to a shift in focus and the winding down of the main contract[165]. - The company anticipates an increase in demand for its products in the subsequent year, despite the decline in gross margin[165]. Research and Development - Research and development expenses for the Aversa Fentanyl product amounted to $3,119,134 for the year ending January 31, 2025, compared to $1,960,425 in the previous year, reflecting increased labor and material costs[167]. - Research and development costs are expensed as incurred, indicating a focus on innovation and product development[201]. Cash and Working Capital - As of January 31, 2025, the company had cash and cash equivalents of $4,311,719 and working capital of $3,811,420, significantly up from $492,942 and $22,770, respectively, as of January 31, 2024[172]. - As of January 31, 2025, the Company had cash and cash equivalents totaling $3,804,000, exceeding federally insured cash balance limits[189]. Impairment and Goodwill - An impairment charge of $3,595,216 was recorded during the year ending January 31, 2025, reducing the value of goodwill and intangible assets[168]. - Goodwill amounted to $1,719,535 as of January 31, 2025, down from $5,021,713 as of January 31, 2024, following an impairment charge of $3,302,478 during the year[194]. - The Company recorded an impairment charge of $293,038 to its intellectual property during the year ending January 31, 2025[193]. Inventory and Accounts Receivable - As of January 31, 2025, the total inventory was $212,041, consisting of work-in-process of $46,255, finished goods of $16,609, and raw materials of $149,177, compared to $168,605 in total inventory as of January 31, 2024[191]. - The Company recorded bad debt expenses of $1,200 and $11,836 for doubtful accounts related to accounts receivable for the years ended January 31, 2025, and 2024, respectively[190]. - The Company maintains allowances for doubtful accounts based on specific identification and historical loss application, reflecting a proactive approach to credit risk management[190]. Accounting Policies - The Company completed necessary changes to its accounting policies and internal controls to comply with lease accounting standards[200]. - The Company recognizes deferred tax assets and liabilities based on the differences between financial statements and tax basis, using enacted tax rates[203]. - The Company applies a straight-line depreciation method for property, plant, and equipment, with useful lives ranging from 3 to 20 years[192].

Core Insights - Nutriband Inc. has received a patent grant in Macao for its AVERSA™ abuse deterrent transdermal technology, enhancing its intellectual property portfolio [1][2][3] - The AVERSA™ technology aims to prevent the abuse and misuse of drugs, particularly opioids, while ensuring accessibility for patients in need [4][6] - The company is collaborating with Kindeva Drug Delivery to develop AVERSA™ Fentanyl, which could potentially achieve peak annual US sales between $80 million and $200 million [5][6] Intellectual Property - The patent J/9010 was granted on February 11, 2025, and is part of a broader international portfolio covering 46 countries, including major markets like the US, Europe, and China [2][3] - Macao's patent system operates independently from mainland China's, providing a unique advantage for Nutriband's technology [2] Product Development - AVERSA™ technology incorporates aversive agents into transdermal patches to mitigate risks associated with drug abuse, including accidental exposure [4][6] - The lead product under development is an abuse-deterrent fentanyl patch, which is designed to be the first of its kind in the market [5][6] Market Potential - The AVERSA™ Fentanyl patch is positioned to address significant market needs in opioid management, with a substantial projected sales range indicating strong market interest [6]

Core Insights - Nutriband Inc. has signed an Associate Partnership agreement with Charlotte FC to enhance brand visibility, particularly for its AI Tape product manufactured locally in Charlotte [1][2] - The partnership aims to promote Nutriband's AVERSA technology, which is positioned as a potential breakthrough in abuse deterrent patches for chronic pain management [3][4] Company Overview - Nutriband Inc. focuses on developing transdermal pharmaceutical products, with its lead product being an abuse deterrent fentanyl patch utilizing AVERSA technology [4] - AVERSA technology is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, and can be integrated into any transdermal patch [4]

Core Insights - Nutriband Inc. has signed an Associate Partnership agreement with Charlotte FC to enhance brand visibility, particularly for its AI Tape product manufactured locally in Charlotte [1][2] - The partnership aims to promote Nutriband's AVERSA platform technology, which is positioned as a potential first-of-its-kind abuse deterrent patch for chronic pain management [3] - Nutriband is focused on developing a portfolio of transdermal pharmaceutical products, with its lead product being an abuse deterrent fentanyl patch utilizing AVERSA technology [4] Company Overview - Nutriband Inc. specializes in transdermal pharmaceutical products, with a manufacturing facility located in North Carolina [2][4] - The AVERSA technology is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, and can be integrated into any transdermal patch [4]

Core Points - Nutriband Inc. has received trademark registration for "Nutriband™" from the USPTO, which is crucial for the commercialization of its AVERSA technology [1][2] - The AVERSA technology aims to prevent the abuse and misuse of drugs, with the lead product being AVERSA™ Fentanyl, a transdermal system designed to deter abuse [2][6] - Nutriband is collaborating with Kindeva Drug Delivery to scale up the commercial manufacturing process for AVERSA™ Fentanyl, which is intended for FDA approval [3] - A market analysis indicates that AVERSA™ Fentanyl could achieve peak annual U.S. sales between $80 million and $200 million, highlighting the potential market impact of the technology [4] - The AVERSA™ technology incorporates aversive agents into transdermal patches to deter drug abuse, particularly for high-abuse-potential medications like fentanyl [5] - Nutriband is focused on developing a range of transdermal pharmaceutical products, with a strong intellectual property portfolio supporting its AVERSA technology [6]

Core Insights - Nutriband has formalized an exclusive product development partnership with Kindeva Drug Delivery to develop Aversa™ Fentanyl, which integrates Nutriband's abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch [1][2] - The partnership involves shared development costs in exchange for milestone payments, indicating a long-term commitment between the two companies [2] Company Overview - Nutriband is focused on developing prescription transdermal pharmaceutical products, with Aversa™ Fentanyl being its lead product under development [5] - The Aversa™ technology aims to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, particularly opioids and stimulants [2][4] Technology Details - Aversa™ abuse-deterrent technology employs a proprietary aversive agent coating that utilizes taste aversion to deter oral abuse and accidental exposure to transdermal opioid and stimulant patches [3] - The technology is protected by a broad international intellectual property portfolio, with patents issued in 46 countries, including the United States, Europe, Japan, and China [3][4] Market Potential - Aversa™ Fentanyl has the potential to be the world's first abuse-deterrent opioid patch, with projected peak annual U.S. sales estimated between $80 million and $200 million [4]

Core Viewpoint - Nutriband Inc. has appointed Olympic medalist Anastasia Nichita to its Product Advisory Board to enhance the brand and promote its sports and consumer products internationally [1][2]. Group 1: Company Overview - Nutriband Inc. specializes in the development of transdermal pharmaceutical products, with a focus on an abuse deterrent fentanyl patch utilizing AVERSA™ technology [4]. - The company produces various products through its subsidiary Pocono Pharma, including AI Tape, which combines traditional kinesiology tape benefits with therapeutic ingredients [3]. Group 2: Strategic Initiatives - The addition of Anastasia Nichita is expected to provide valuable insights and experience to strengthen Nutriband's consumer product categories globally [2].

Core Viewpoint - Nutriband Inc. has received a Notice of Allowance from the USPTO for its patent application related to the Aversa™ abuse deterrent technology, which is expected to enhance its intellectual property protection in the U.S. for transdermal products aimed at preventing drug abuse and misuse [1][2][4]. Group 1: Technology Overview - The Aversa™ abuse deterrent technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, including opioids and stimulants [3][6]. - This technology employs a proprietary aversive agent coating that utilizes taste aversion to deter oral abuse and accidental exposure to transdermal products [3][6]. Group 2: Product Development - Nutriband's lead product under development is Aversa™ Fentanyl, which aims to be the first abuse deterrent fentanyl transdermal system on the market [2][5]. - Aversa™ Fentanyl has the potential to achieve peak annual U.S. sales ranging from $80 million to $200 million [5]. Group 3: Intellectual Property - The Aversa™ technology is protected by a broad international intellectual property portfolio, with patents issued in 46 countries, including the U.S., Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia [1][4][6].

Core Insights - Nutriband is planning to file for FDA approval for its AVERSA™ Fentanyl product in the first half of 2025 [1] - The AVERSA™ technology aims to deter abuse and misuse of transdermal fentanyl patches, potentially improving safety for patients [4][11] - The technology is protected by a broad intellectual property portfolio with patents granted in 46 countries, including major markets [10][15] Company Developments - Nutriband is collaborating with Kindeva Drug Delivery to develop AVERSA™ Fentanyl, which integrates Nutriband's abuse-deterrent technology into an FDA-approved transdermal system [3] - The company has completed the registration requirements to extend its Chinese patent to Macao, enhancing its intellectual property protection [9] - AVERSA™ Fentanyl is projected to achieve peak annual sales in the U.S. ranging from $80 million to $200 million [12] Technology Overview - The AVERSA™ abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent drug abuse and accidental exposure [4][11] - This technology is designed to maintain accessibility for patients who genuinely need these medications while reducing the risk of misuse [4][11] - The technology's broad patent coverage includes regions such as Hong Kong and Macao, in addition to other major markets [10][15]